NCT05641545
Recruiting
Phase 1
IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint Inhibitor in Advanced/Metastatic RCC Patients
SLK Kliniken Heilbronn GmbH1 site in 1 country10 target enrollmentStarted: October 17, 2022Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- SLK Kliniken Heilbronn GmbH
- Enrollment
- 10
- Locations
- 1
- Primary Endpoint
- Primary endpoint is "success of treatment" defined as a patient without unacceptable toxicity and showing a vaccination-induced T-cell response.
Overview
Brief Summary
This is a monocenter, single-arm, prospective phase Ib trial, designed to evaluate the safety, clinical toxicity and in vivo immunological effects of a patient-individualized peptide vaccination added to standard of care checkpoint blockade (nivolumab) in adult patients with metastatic/advanced renal cell carcinoma who experienced at least stable disease after four cycles of standard of care immune therapy (ipilimumab/nivolumab).
Detailed Description
The aim of this clinical study is to evaluate the feasibility and safety of an individualized peptide vaccination approach in patients with advanced renal cell carcinoma who experienced at least stable disease after four cycles of standard of care immune therapy (ipilimumab/nivolumab). For this purpose, tumor-specific mutations are analyzed by comparative exome sequencing of tumor and healthy reference tissue. In a second step, HLA-binding (human leukocyte antigen-binding) peptides derived from mutated protein sequences are selected for vaccination. The peptides are administered as a vaccination cocktail with adjuvant GM-CSF and Imiquimod over a course of 9 months and a total of 16 vaccinations. Primary objective is the de novo induction of a specific T cell response without unacceptable toxicity.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Other
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age 18 or older
- •Ability to understand and willingness to sign a written informed consent document.
- •Patients with RCC Stage IV (AJCC 8th ed.) of any histology, not amenable to curative surgery, minimal-invasive therapy or radiation therapy
- •Intermediate/poor risk by IMDC (≥1 risk factors)
- •Patients with advanced or metastatic disease occurring subsequent to initial curative nephrectomy or subsequent to other previous therapy with curative intent are eligible
- •Measurable disease as per RECIST 1.1 (at least one measurable lesion)
- •Participants must be eligible to be treated with first line Nivolumab+Ipilimumab based on investigator´s judgement.
- •Patients must have adequate fresh tissue available. If a fresh tissue sample is not available by routine procedures, participants must have a lesion amenable to fresh tumor biopsy at study entry for the next generation sequencing (NGS) required for this study and willing to provide informed consent for such biopsy. FFPE tumor samples are not suitable for the NGS required for this study.
- •Patient is agreeable to allow tumor and blood samples to be submitted for complete exome and transcriptome sequencing.
- •No previous systemic therapy for advanced or metastatic RCC
Exclusion Criteria
- •Prior treatment with any anti-programmed cell death (anti-PD-1), or anti-programmed cell death ligand 1 (anti-PD-L1) agent or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways.
- •Prior systemic anti-cancer therapy for RCC with vascular endothelial growth factor (VEGF)/VEGF receptors (VEGFR) or mechanistic target of rapamycin (mTOR) targeting agents. Prior systemic anti-cancer therapy for curative intent with VEGFR or mTOR targeting agents is allowed if discontinued \>6 months prior to enrolment.
- •Prior RCC-directed cancer vaccine therapy.
- •Any history of a known or suspected autoimmune disease \[e.g. including but not limited to inflammatory bowel diseases, rheumatoid arthritis, autoimmune thyroiditis, autoimmune hepatitis, systemic sclerosis (scleroderma and variants), systemic lupus erythematosus, autoimmune vasculitis, autoimmune neuropathies (such as Guillain-Barre syndrome) or recent history of a syndrome that required systemic corticosteroids (\> 10 mg daily prednisone equivalent) or immunosuppressive medications except for syndromes which would not be expected to recur in the absence of an external trigger. Participants with vitiligo or type I diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll.
- •Any condition requiring systemic treatment with corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroid doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •Active brain metastases or leptomeningeal metastases
- •Positive serological test for hepatitis C virus ot hepatitis B virus surface antigen (HBsAg) or or human immunodeficiency virus (HIV)
- •Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring IV antibiotic treatment, symptomatic congestive heart failure, unstable angina pectoris, clinically relevant cardiac arrhythmia.
- •Any known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug administration or interfere with the interpretation of safety results.
Arms & Interventions
IVAC-RCC-001
Experimental
Individual peptide vaccination with adjuvant GM-CSF and Imiquimod Intradermal injection of a cocktail of 3-5 individual HLA-binding peptides. Subcutaneous injection of adjuvant GM-CSF at vaccination site. Topical administration of Imiquimod at vaccination site.
Intervention: IVAC (Biological)
Outcomes
Primary Outcomes
Primary endpoint is "success of treatment" defined as a patient without unacceptable toxicity and showing a vaccination-induced T-cell response.
Time Frame: 120 days
Treatment success is defined as a patient without 1. unacceptable toxicities (grade 4 according to NCI-CTC) and in whom 2. a vaccine-specific response of CD4+ and/or CD8+ T cells could be induced. The primary endpoint will be analyzed after 10 patients have reached visit 10
Secondary Outcomes
- To evaluate CD4+ and/or CD8+ T-cell responses over the vaccination period.(246 days)
- To evaluate the event-free survival (EFS) during and after treatment.(246 days)
Investigators
Uwe Martens
Director of the Department of Hematology, Oncology and Palliative Care
SLK Kliniken Heilbronn GmbH
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Phase 1
Neoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerPancreatic Cancer MetastaticColorectal Cancer MetastaticNCT04799431Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting
Phase 1
Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid TumorsAdvanced Malignant Solid TumorNCT04864379Sir Run Run Shaw Hospital30
Recruiting
Phase 1
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Merkel Cell Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Merkel Cell Carcinoma AJCC v8Clinical Stage IVA Gastric Cancer AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastric Cancer AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Cervical CarcinomaLocally Advanced Endometrial CarcinomaLocally Advanced Gastric AdenocarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaLocally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Hepatocellular CarcinomaLocally Advanced Lung Non-Small Cell CarcinomaLocally Advanced Malignant Solid NeoplasmLocally Advanced MelanomaLocally Advanced Merkel Cell CarcinomaLocally Advanced Renal Cell CarcinomaLocally Advanced Skin Squamous Cell CarcinomaLocally Advanced Triple-Negative Breast CarcinomaLocally Advanced Unresectable Breast CarcinomaLocally Advanced Unresectable Cervical CarcinomaLocally Advanced Unresectable Gastric AdenocarcinomaLocally Advanced Unresectable Gastroesophageal Junction AdenocarcinomaLocally Advanced Unresectable Renal Cell CarcinomaLocally Advanced Urothelial CarcinomaMetastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Gastric AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Merkel Cell CarcinomaMetastatic Renal Cell CarcinomaMetastatic Skin Squamous Cell CarcinomaMetastatic Triple-Negative Breast CarcinomaMetastatic Urothelial CarcinomaSkin Squamous Cell CarcinomaStage III Cervical Cancer AJCC v8Stage III Hepatocellular Carcinoma AJCC v8Stage III Lung Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIA Hepatocellular Carcinoma AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIA Uterine Corpus Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IIIB Hepatocellular Carcinoma AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIB Uterine Corpus Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IIIC Uterine Corpus Cancer AJCC v8Stage IIIC1 Uterine Corpus Cancer AJCC v8Stage IIIC2 Uterine Corpus Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8Stage IVA Hepatocellular Carcinoma AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVA Uterine Corpus Cancer AJCC v8Stage IVB Cervical Cancer AJCC v8Stage IVB Hepatocellular Carcinoma AJCC v8Stage IVB Lung Cancer AJCC v8Stage IVB Uterine Corpus Cancer AJCC v8Triple-Negative Breast CarcinomaUnresectable Cervical CarcinomaUnresectable Endometrial CarcinomaUnresectable Gastric AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaUnresectable Head and Neck Squamous Cell CarcinomaUnresectable Hepatocellular CarcinomaUnresectable Lung Non-Small Cell CarcinomaUnresectable Malignant Solid NeoplasmUnresectable MelanomaUnresectable Merkel Cell CarcinomaUnresectable Renal Cell CarcinomaUnresectable Skin Squamous Cell CarcinomaUnresectable Triple-Negative Breast CarcinomaUnresectable Urothelial CarcinomaNCT05269381Mayo Clinic132
Unknown
Phase 1
A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular CarcinomaHepatocellular CarcinomaLiver Cancer, AdultNCT03674073Chinese PLA General Hospital24
Suspended
Phase 1
Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSquamous Cell Lung CancerSquamous Non-small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckNCT04266730UNC Lineberger Comprehensive Cancer Center6